Open AccessEffect of evolocumab on the progression and stability of atherosclerotic plaques as evaluated by grayscale and iMAP-IVUS
Author(s) -
Qingzan Kong,
Miao Liu,
Yueyan Li,
Qing Zhu,
Su G
Publication year - 2020
Publication title -
annals of palliative medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.546
H-Index - 19
eISSN - 2224-5839
pISSN - 2224-5820
DOI - 10.21037/apm-20-690
Subject(s) - medicine , grayscale , evolocumab , cardiology , artificial intelligence , image (mathematics) , cholesterol , apolipoprotein b , apolipoprotein a1 , computer science
Evolocumab inhibits the proprotein convertase subtilisin/kexin type 9 protein and is a potent cholesterol-lowering drug. However, the relationship between evolocumab and inflammation, and the effects of evolocumab on the stability of atherosclerotic plaques remain unknown.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom